Valtuille Zaba, Acquaviva Eric, Trebossen Vincent, Ouldali Naim, Bourmaud Aurelie, Sclison Stéphane, Gomez Alexandre, Revet Alexis, Peyre Hugo, Delorme Richard, Kaguelidou Florentia
Center of Clinical Investigations, Inserm CIC1426, Robert Debré University Hospital, APHP.Nord, Paris, France; EA7323 Perinatal and Pediatric Pharmacology and Therapeutic Assessment, Paris Cité University, Paris, France.
Department of Child and Adolescent Psychiatry, Robert Debré University Hospital, APHP.Nord, Paris Cité University, Paris, France.
J Pediatr. 2025 May;280:114502. doi: 10.1016/j.jpeds.2025.114502. Epub 2025 Feb 5.
To assess rates and trends of hypnotic medication prescriptions for children and adolescents.
Cross-sectional study of national dispensing data between January 1, 2016, and December 31, 2023, in France. Prescriptions of hypnotic medications (hydroxyzine, alimemazine, melatonin, and Z-drugs) dispensed to children aged 6-17 years were analyzed. Monthly rates of hypnotic prescriptions per 1000 children were modeled before and after the pandemic onset (March 2020) to assess rate and trend changes. Rate ratios (RRs) were calculated between estimated and expected prescription rates.
Overall, 2 675 142 prescriptions were dispensed to an average yearly population of 9 963 497 children. In January 2016, prescription rate of hypnotic medications was estimated at 1.9 per 1000 and at 6.8 per 1000 in December 2023, with postpandemic onset rates exceeding the expected by 131% (RR: 2.31, 95% CI: 2.08; 2.54). Prescription trends increased for all medications from -0.1% (95% CI: -0.2; 0.1%) per month prepandemic to +1.4% (95% CI: 1.2; 1.6%) after the pandemic onset for hydroxyzine; +0.1% (95% CI: 0.0; 0.2%) to +0.9% (95% CI: 0.7; 1.0%) for alimemazine; +2.2% (95% CI: 2.0; 2.3%) to +4.4% (95% CI: 3.9; 4.9%) for melatonin; and -3.2% (95% CI: -3.6;-2.8%) to +1.8% (95% CI: 1.4; 2.2%) for Z-drugs. Monthly prescription rates exceeded the expected by 38% (RR: 1.38, 95% CI: 1.31; 1.46) for hydroxyzine; 19% (RR: 1.19, 95% CI: 1.15; 1.22) for alimemazine; 344% (RR: 4.44, 95% CI: 4.07; 4.80) for melatonin; and 419% (RR: 5.19, 95% CI: 4.24; 6.14) for Z-drugs.
Recent substantial increases in hypnotic medication prescribing for children are possibly related to their persistently deteriorating mental health, changes in prescribing strategies, and/or unmet pre-existing needs.
评估儿童和青少年催眠药物处方的开具率及趋势。
对2016年1月1日至2023年12月31日期间法国的全国配药数据进行横断面研究。分析了给6至17岁儿童开具的催眠药物(羟嗪、阿利马嗪、褪黑素和Z类药物)处方。对大流行开始前(2020年3月)和之后每1000名儿童的催眠处方月率进行建模,以评估开具率和趋势变化。计算估计处方率与预期处方率之间的率比(RRs)。
总体而言,共为平均每年9963497名儿童开具了2675142张处方。2016年1月,催眠药物的处方率估计为每1000人1.9张,2023年12月为每1000人6.8张,大流行开始后的开具率比预期高出131%(RR:2.31,95%CI:2.08;2.54)。所有药物的处方趋势均有所增加,羟嗪从大流行前每月-0.1%(95%CI:-0.2;0.1%)增至大流行开始后+1.4%(95%CI:1.2;1.6%);阿利马嗪从+0.1%(95%CI:0.0;0.2%)增至+0.9%(95%CI:0.7;1.0%);褪黑素从+2.2%(95%CI:2.0;2.3%)增至+4.4%(95%CI:3.9;4.9%);Z类药物从-3.2%(95%CI:-3.6;-2.8%)增至+1.8%(95%CI:1.4;2.2%)。羟嗪的月处方率比预期高出38%(RR:1.38,95%CI:1.31;1.46);阿利马嗪高出19%(RR:1.19,95%CI:1.15;1.22);褪黑素高出344%(RR:4.44,95%CI:4.07;4.80);Z类药物高出419%(RR:5.19,95%CI:4.24;6.14)。
近期儿童催眠药物处方量的大幅增加可能与其持续恶化的心理健康状况、处方策略的变化和/或先前未满足的需求有关。